Bone drug shows promise for rare mast cell disorder
NCT ID NCT03401060
First seen Apr 11, 2026 · Last updated Jun 12, 2026 · Updated 11 times
Summary
This study tested whether denosumab, a drug given as a shot every 6 months, can improve bone density in people with osteoporosis caused by systemic mastocytosis. 24 adults with the condition took part. The goal was to see if the drug strengthens bones and prevents fractures better than a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Caen Hospital, Clinical haematology department
Caen, 14033, France
-
Cochin Hospital, Rheumatology department
Paris, 75014, France
-
Estaing Hospital, Cellular therapy and clinical haematology department
Clermont-Ferrand, 63100, France
-
Jean Minjoz Hospital, Dermatology department
Besançon, 25030, France
-
La Pitié-Salpêtrière Hospital, Internal medicine and clinical immunology department
Paris, 75013, France
-
La Timone Hospital, Dermatology and cutaneous oncology department
Marseille, 13385, France
-
Lapeyronie Hospital, Rheumatology and Immunology department
Montpellier, 34295, France
-
Lille CHRU Hospital, Internal medicine and clinical immunology department
Lille, 59037, France
-
Necker Hospital, Adult haematology department
Paris, 75015, France
-
Strasbourg Hospital, Rheumatology department
Strasbourg, 67098, France
-
Toulouse Hospital, Dermatology department
Toulouse, 31060, France
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.